Non-aspirin non-steroidal anti-inflammatory drugs for the primary chemoprevention of non-gastrointestinal cancer: Summary of evidence

Current Pharmaceutical Design

Volumn 18, Issue 26, 2012, Pages 4047-4070

  Silva, Marcus Tolentino ^a,b   Galvao, Tais Freire ^a,c   Zimmerman, Ivan Ricardo ^a   Pereira, Mauricio Gomes ^a   Lopes, Luciane Cruz ^d  

^a UNIVERSITY OF BRASILIA   (Brazil)

^b MINISTÉRIO DA SAÚDE   (Brazil)

^c FEDERAL UNIVERSITY OF AMAZONAS   (Brazil)

^d UNIVERSITY OF SOROCABA   (Brazil)

Author keywords

Chemoprevention; Neoplasms; Non aspirin; Non gastrointestinal; Non steroidal anti inflammatory agents; Primary prevention

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; NON ASPIRIN NONSTEROID ANTIINFLAMMATORY AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; UNCLASSIFIED DRUG;

ACTINIC KERATOSIS; ARTICLE; BASAL CELL CARCINOMA; BLADDER CANCER; BREAST CANCER; CANCER PREVENTION; CANCER RISK; CARDIOVASCULAR DISEASE; CHEMOPROPHYLAXIS; DOSE RESPONSE; DRUG EFFICACY; ENDOMETRIUM CANCER; ENZYME INHIBITION; HEAD AND NECK CANCER; HUMAN; KIDNEY CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; NEOPLASM; NON GASTROINTESTINAL CANCER; NON MELANOMA SKIN CANCER; OBSERVATIONAL STUDY; OVARY CANCER; PRIMARY PREVENTION; PRIORITY JOURNAL; PROSTATE CANCER; SKIN CANCER; SQUAMOUS CELL CARCINOMA; TRANSITIONAL CELL CARCINOMA; TREATMENT DURATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CHEMOPREVENTION; COLORECTAL NEOPLASMS; HUMANS; NEOPLASMS; PRIMARY PREVENTION; RISK;

EID: 84864566642     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212802083699     Document Type: Article

References (102)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Sporn MB. Approaches to prevention of epithelial cancer during the preneoplastic period. Cancer Res 1976; 36: 2699-702.
3. Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 2011; 377: 31-41.
4. Cuzick J, Otto F, Baron JA, et al. Aspirin and non-steroidal antiinflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol 2009; 10: 501-7.
5. Cooper K, Squires H, Carroll C, et al. Chemoprevention of colorectal cancer: systematic review and economic evaluation. Health Technol Assess 2010; 14: 1-206.
6. González-Pérez A, García Rodríguez LA, López-Ridaura R. Effects of non-steroidal anti-inflammatory drugs on cancer sites other than the colon and rectum: a meta-analysis. BMC Cancer 2003; 3: 28.
7. Ulrich CM, Bigler J, Potter JD. Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nat Rev Cancer 2006; 6: 130-40.
8. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971; 231: 232-5.
9. Vane JR. Adventures and excursions in bioassay: the stepping stones to prostacyclin. Nobel Lecture, 8 December 1982. Biosci Rep 1983; 3: 683-711.
10. Williams CS, Mann M, DuBois RN. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 1999; 18: 7908-16.
11. Miyamoto T, Ogino N, Yamamoto S, Hayaishi O. Purification of prostaglandin endoperoxide synthetase from bovine vesicular gland microsomes. J Biol Chem 1976; 251: 2629-36.
12. Simmons DL, Levy DB, Yannoni Y, Erikson RL. Identification of a phorbol ester-repressible v-src-inducible gene. Proc Natl Acad Sci USA 1989; 86: 1178-82.
13. Kujubu DA, Fletcher BS, Varnum BC, Lim RW, Herschman HR. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem 1991; 266: 12866-72.
14. Hirst JJ, Teixeira FJ, Zakar T, Olson DM. Prostaglandin endoperoxide-H synthase-1 and-2 messenger ribonucleic acid levels in human amnion with spontaneous labor onset. J Clin Endocrinol Metab 1995; 80: 517-23.
15. Gosh N, Chaki R, Mandal V, Mandal S. COX-2 as a target for cancer chemotherapy. Pharmacol Rep 2010; 62: 233-44.
16. Ong CK, Lirk P, Tan CH, Seymour RA. An evidence-based update on nonsteroidal anti-inflammatory drugs. Clin Med Res 2007; 5: 19-34.
17. Gupta RA, Dubois RN. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 2001; 1: 11-21.
18. Buchanan FG, Wang D, Bargiacchi F, DuBois RN. Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J Biol Chem 2003; 278: 35451-7.
19. Han C, Wu T. Cyclooxygenase-2-derived prostaglandin E2 promotes human cholangiocarcinoma cell growth and invasion through EP1 receptor-mediated activation of the epidermal growth factor receptor and Akt. J Biol Chem 2005; 280: 24053-63.
20. Chapple KS, Cartwright E, Hawcroft G, et al. Localization of cyclooxygenase-2 in human sporadic colorectal adenomas. Am J Pathol 2000; 156: 545-53.
21. Koki A, Leahy K, Masferrer J. Potential utility of COX-2 inhibitors in chemoprevention and chemotherapy. Expert Opin Investig Drugs 1999; 8: 1623-38.
22. Dempke W, Rie C, Grothey A, Schmoll H. Cyclooxigenase-2: a novel target for cancer chemotherapy? Cancer Res Clin Oncol 2001; 127: 411-7.
23. Harris RE. Cyclooxygenase-2 (cox-2) and the inflammogenesis of cancer. Subcell Biochem 2007; 42: 93-126.
24. Harris RE. Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung. Inflammopharmacology 2009; 17: 55-67.
25. Chulada P, Thompson M, Mahler J, et al. Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res 2000; 60: 4705-8.
26. Guyatt G, Rennie D, Meade MO, Cook JD. Users' Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice. American Medical Association: New York 2008.
27. Tavani A, Gallus S, La Vecchia C, Conti E, Montella M, Franceschi S. Aspirin and ovarian cancer: an Italian case-control study. Ann Oncol 2000; 11: 1171-3.
28. Akhmedkhanov A, Toniolo P, Zeleniuch-Jacquotte A, Kato I, Koenig KL, Shore RE. Aspirin and epithelial ovarian cancer. Prev Med 2001; 33: 682-7.
29. Moysich KB, Baker JA, Rodabaugh KJ, Villella JA. Regular analgesic use and risk of endometrial cancer. Cancer Epidemiol Biomarkers Prev 2005; 14: 2923-8.
30. Lerner SP, Lee JJ, Liu S, et al. Results of a Phase II/IIIg trial of celecoxib to prevent recurrence of non-muscle invasive bladder cancer. J Urol 2009; 181: 71.
31. Grau MV, Baron JA, Langholz B, et al. Effect of NSAIDs on the recurrence of nonmelanoma skin cancer. Int J Cancer 2006; 119: 682-6.
32. Cramer DW, Harlow BL, Titus-Ernstoff L, Bohlke K, Welch WR, Greenberg ER. Over-the-counter analgesics and risk of ovarian cancer. Lancet 1998; 351: 104-7.
33. Rosenberg L, Palmer JR, Rao RS, et al. A case-control study of analgesic use and ovarian cancer. Cancer Epidemiol Biomarkers Prev 2000; 9: 933-7.
34. Moysich KB, Mettlin C, Piver MS, Natarajan N, Menezes RJ, Swede H. Regular use of analgesic drugs and ovarian cancer risk. Cancer Epidemiol Biomarkers Prev 2001; 10: 903-6.
35. Fairfield KM, Hunter DJ, Fuchs CS, Colditz GA, Hankinson SE. Aspirin, other NSAIDs, and ovarian cancer risk (United States). Cancer Causes Control 2002; 13: 535-42.
36. Sørensen HT, Friis S, Nørgård B, et al. Risk of cancer in a large cohort of nonaspirin NSAID users: a population-based study. Br J Cancer 2003; 88: 1687-92.
37. Lacey JV, Sherman ME, Hartge P, Schatzkin A, Schairer C. Medication use and risk of ovarian carcinoma: a prospective study. Int J Cancer 2004; 108: 281-6.
38. Hayes JH, Anderson KE, Folsom AR. Association between nonsteroidal anti-inflammatory drug use and the incidence of lung cancer in the Iowa women's health study. Cancer Epidemiol Biomarkers Prev 2006; 15: 2226-31.
39. Hernández-Díaz S, García Rodríguez LA. Nonsteroidal antiinflammatory drugs and risk of lung cancer. Int J Cancer 2007; 120: 1565-72.
40. Gray J, Mao JT, Szabo E, Kelley M, Kurie J, Bepler G, Physicians ACoC. Lung cancer chemoprevention: ACCP evidence-based clinical practice guidelines (2nd Edition). Chest 2007; 132: 56S-68S.
41. Khuder SA, Herial NA, Mutgi AB, Federman DJ. Nonsteroidal antiinflammatory drug use and lung cancer: a metaanalysis. Chest 2005; 127: 748-54.
42. Olsen JH, Friis S, Poulsen AH, et al. Use of NSAIDs, smoking and lung cancer risk. Br J Cancer 2008; 98: 232-7.
43. Slatore CG, Au DH, Littman AJ, Satia JA, White E. Association of nonsteroidal anti-inflammatory drugs with lung cancer: results from a large cohort study. Cancer Epidemiol Biomarkers Prev 2009; 18: 1203-7.
44. Xu J, Yin Z, Gao W, et al. Meta-analysis on the association between nonsteroidal anti-inflammatory drug use and lung cancer risk. Clin Lung Cancer 2012; 13(1): 44-51.
45. Agrawal A, Fentiman IS. NSAIDs and breast cancer: a possible prevention and treatment strategy. Int J Clin Pract 2008; 62: 444-9.
46. Crew KD, Neugut AI. Aspirin and NSAIDs: effects in breast and ovarian cancers. Curr Opin Obstet Gynecol 2006; 18: 71-5.
47. Singh-Ranger G, Mokbel K. Current concepts in cyclooxygenase inhibition in breast cancer. J Clin Pharm Ther 2002; 27: 321-7.
48. Zhao YS, Zhu S, Li XW, et al. Association between NSAIDs use and breast cancer risk: a systematic review and meta-analysis. Breast Cancer Res Treat 2009; 117: 141-50.
49. Khuder SA, Mutgi AB. Breast cancer and NSAID use: a metaanalysis. Br J Cancer 2001; 84: 1188-92.
50. Takkouche B, Regueira-Méndez C, Etminan M. Breast cancer and use of nonsteroidal anti-inflammatory drugs: a meta-analysis. J Natl Cancer Inst 2008; 100: 1439-47.
51. Cuzick J, Decensi A, Arun B, et al. Preventive therapy for breast cancer: a consensus statement. Lancet Oncology 2011; 12: 496-503.
52. Deffieux X, Touboul C, Uzan C, et al. [Chemoprevention and prophylactic surgery in ovarian carcinoma]. J Gynecol Obstet Biol Reprod (Paris) 2007; 36: 756-63.
53. Brekelmans CT. Risk factors and risk reduction of breast and ovarian cancer. Curr Opin Obstet Gynecol 2003; 15: 63-8.
54. Barnes MN, Grizzle WE, Grubbs CJ, Partridge EE. Paradigms for primary prevention of ovarian carcinoma. CA Cancer J Clin 2002; 52: 216-25.
55. Bonovas S, Filioussi K, Sitaras NM. Do nonsteroidal antiinflammatory drugs affect the risk of developing ovarian cancer? A meta-analysis. Br J Clin Pharmacol 2005; 60: 194-203.
56. Schildkraut JM, Moorman PG, Halabi S, Calingaert B, Marks JR, Berchuck A. Analgesic drug use and risk of ovarian cancer. Epidemiology 2006; 17: 104-7.
57. Wernli KJ, Newcomb PA, Hampton JM, Trentham-Dietz A, Egan KM. Inverse association of NSAID use and ovarian cancer in relation to oral contraceptive use and parity. Br J Cancer 2008; 98: 1781-3.
58. Lurie G, Terry KL, Wilkens LR, et al. Pooled analysis of the association of PTGS2 rs5275 polymorphism and NSAID use with invasive ovarian carcinoma risk. Cancer Causes Control 2010; 21: 1731-41.
59. Hannibal CG, Rossing MA, Wicklund KG, Cushing-Haugen KL. Analgesic drug use and risk of epithelial ovarian cancer. Am J Epidemiol 2008; 167: 1430-7.
60. Merritt MA, Green AC, Nagle CM, Webb PM, Cancer) ACSO, Group AOCS. Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer. Int J Cancer 2008; 122: 170-6.
61. Pinheiro SP, Tworoger SS, Cramer DW, Rosner BA, Hankinson SE. Use of nonsteroidal antiinflammatory agents and incidence of ovarian cancer in 2 large prospective cohorts. Am J Epidemiol 2009; 169: 1378-87.
62. Prizment AE, Folsom AR, Anderson KE. Nonsteroidal antiinflammatory drugs and risk for ovarian and endometrial cancers in the Iowa Women's Health Study. Cancer Epidemiol Biomarkers Prev 2010; 19: 435-42.
63. Danforth KN, Gierach GL, Brinton LA, et al. Nonsteroidal antiinflammatory drug use and endometrial cancer risk in the NIHAARP Diet and Health Study. Cancer Prev Res (Phila) 2009; 2: 466-72.
64. Viswanathan AN, Feskanich D, Schernhammer ES, Hankinson SE. Aspirin, NSAID, and acetaminophen use and the risk of endometrial cancer. Cancer Res 2008; 68: 2507-13.
65. Bodelon C, Doherty JA, Chen C, Rossing MA, Weiss NS. Use of nonsteroidal antiinflammatory drugs and risk of endometrial cancer. Am J Epidemiol 2009; 170: 1512-7.
66. Fortuny J, Sima C, Bayuga S, et al. Risk of endometrial cancer in relation to medical conditions and medication use. Cancer Epidemiol Biomarkers Prev 2009; 18: 1448-56.
67. Daugherty SE, Pfeiffer RM, Sigurdson AJ, et al. Nonsteroidal antiinflammatory drugs and bladder cancer: a pooled analysis. Am J Epidemiol 2011; 173: 721-30.
68. Atkins MB, Choueiri TK. Epidemiology, pathology, and pathogenesis of renal cell carcinoma In: Basow DS, ed. UpToDate. UpToDate: Waltham 2011.
69. Cho E, Hankinson SE, Curhan G, Atkins MB, Stampfer M, Choueiri TK. Prospective study of use of analgesics in relation to the risk of renal cell cancer: The Nurses' Health Study and Health Professionals Follow-up Study [abstract]. In: Proceedings of the 100th Annual Meeting of the American. AACR: Philadelphia (PA) 2009.
70. Gago-Dominguez M, Yuan JM, Castelao JE, Ross RK, Yu MC. Regular use of analgesics is a risk factor for renal cell carcinoma. Br J Cancer 1999; 81: 542-8.
71. Mahmud SM, Franco EL, Aprikian AG. Use of nonsteroidal antiinflammatory drugs and prostate cancer risk: a meta-analysis. Int J Cancer 2010; 127: 1680-91.
72. Mahmud S, Franco E, Aprikian A. Prostate cancer and use of nonsteroidal anti-inflammatory drugs: systematic review and metaanalysis. Br J Cancer 2004; 90(1): 93-9.
73. Jafari S, Etminan M, Afshar K. Nonsteroidal anti-inflammatory drugs and prostate cancer: a systematic review of the literature and meta-analysis. Can Urol Assoc J 2009; 3: 323-30.
74. Siemes C, Visser LE, Coebergh JW, Hofman A, Uitterlinden AG, Stricker BH. Protective effect of NSAIDs on cancer and influence of COX-2 C(-765G) genotype. Curr Cancer Drug Targets 2008; 8: 753-64.
75. Brasky TM, Velicer CM, Kristal AR, Peters U, Potter JD, White E. Nonsteroidal anti-inflammatory drugs and prostate cancer risk in the VITamins And Lifestyle (VITAL) cohort. Cancer Epidemiol Biomarkers Prev 2010; 19: 3185-8.
76. Jacobs EJ, Newton CC, Stevens VL, Gapstur SM. A large cohort study of long-term acetaminophen use and prostate cancer incidence. Cancer Epidemiol Biomarkers Prev 2011; 20: 1322-8.
77. Algotar AM, Thompson PA, Ranger-Moore J, et al. Effect of aspirin, other NSAIDs, and statins on PSA and PSA velocity. Prostate 2010; 70: 883-8.
78. Salinas CA, Kwon EM, FitzGerald LM, et al. Use of aspirin and other nonsteroidal antiinflammatory medications in relation to prostate cancer risk. Am J Epidemiol 2010; 172: 578-90.
79. Coogan PF, Kelly JP, Strom BL, Rosenberg L. Statin and NSAID use and prostate cancer risk. Pharmacoepidemiol Drug Saf 2010; 19: 752-5.
80. Murad AS, Down L, Davey Smith G, et al. Associations of aspirin, nonsteroidal anti-inflammatory drug and paracetamol use with PSA-detected prostate cancer: findings from a large, populationbased, case-control study (the ProtecT study). Int J Cancer 2011; 128: 1442-8.
81. Fowke JH, Motley SS, Smith JA, et al. Association of nonsteroidal anti-inflammatory drugs, prostate specific antigen and prostate volume. J Urol 2009; 181: 2064-70.
82. Friedman ES, LaNatra N, Stiller MJ. NSAIDs in dermatologic therapy: review and preview. J Cutan Med Surg 2002; 6: 449-59.
83. Elmets CA, Viner JL, Pentland AP, et al. Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, doubleblind, placebo-controlled trial. J Natl Cancer Inst 2010; 102: 1835-44.
84. Nunes AP, Lapane KL, Weinstock MA, Group VT. Association between non-steroidal anti-inflammatory drugs and keratinocyte carcinomas of the skin among participants in the Veterans Affairs Topical Tretinoin Chemoprevention Trial. Pharmacoepidemiol Drug Saf 2011; 20: 922-9.
85. Clouser MC, Roe DJ, Foote JA, Harris RB. Effect of non-steroidal anti-inflammatory drugs on non-melanoma skin cancer incidence in the SKICAP-AK trial. Pharmacoepidemiol Drug Saf 2009; 18: 276-83.
86. Torti DC, Christensen BC, Storm CA, et al. Analgesic and nonsteroidal anti-inflammatory use in relation to nonmelanoma skin cancer: a population-based case-control study. J Am Acad Dermatol 2011; 65: 304-12.
87. Cahoon E, Rajaraman P, Alexander B, Doody M, Linet M, Freedman D. Use of non-steroidal anti-inflammatory drugs and risk of basal cell carcinoma in the united states radiologic technologists study. Int J Cancer 2012; 130(12): 2939-48.
88. Vogel U, Christensen J, Wallin H, Friis S, Nexø BA, Tjønneland A. Polymorphisms in COX-2, NSAID use and risk of basal cell carcinoma in a prospective study of Danes. Mutat Res 2007; 617: 138-46.
89. Lim JL, Stern RS. Epidemiology and clinical features of cutaneous squamous cellcarcinoma. In: Basow DS, ed. UpToDate. UpToDate: Waltham 2011.
90. Geller AC, Swetter S. Primary prevention of melanoma. In: Basow DS, Ed. UpToDate. UpToDate: Waltham 2011.
91. Francis SO, Mahlberg MJ, Johnson KR, Ming ME, Dellavalle RP. Melanoma chemoprevention. Journal of the American Academy of Dermatology 2006; 55: 849-61.
92. Jeter JM, Bonner JD, Johnson TM, Gruber SB. Nonsteroidal antiinflammatory drugs and risk of melanoma. J Skin Cancer 2011; 2011: 598571.
93. Wilson JC, Anderson LA, Murray LJ, Hughes CM. Non-steroidal anti-inflammatory drug and aspirin use and the risk of head and neck cancer: a systematic review. Cancer Causes Control 2011; 22: 803-10.
94. Kehoe S, Morrison J. Ovarian cancer (advanced). Clin Evid (Online) 2009; 2009.
95. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-917.
96. Chen L, Berek JS. Endometrial cancer: Epidemiology, risk factors, clinical features, diagnosis, and screening In: Basow DS, Ed. UpToDate. UpToDate: Waltham 2011.
97. Jimenez JA, Campbell SC, Jones JS. In: Basow DS, ed. UpToDate. UpToDate: Waltham 2011.
98. NICE. Bevacizumab (first-line), sorafenib (first-and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma. National Institute for Health and Clinical Excellence: London 2011.
99. Crawford ED. Chemoprevention strategies in prostate cancer. In: Basow DS, Ed. UpToDate. UpToDate: Waltham 2011.
100. Ormerod A, Rajpara S, Craig F. Basal cell carcinoma. Clin Evid (Online) 2010; 2010.
101. Rudin CM, Marur S. Chemoprevention in oral dysplasia and head and neck cancer. In: Basow DS, ed. UpToDate. UpToDate: Waltham 2011.
102. Cho E, Hankinson SE, Curhan G, Atkins MB, Stampfer M, Choueiri TK eds. Prospective study of use of analgesics in relation to the risk of renal cell cancer: The Nurses' Health Study and Health Professionals Follow-up Study [abstract]. In: Proceedings of the 100th Annual Meeting of the American. AACR: Philadelphia (PA) 2009.